Search

Central receipt of investigational product

Author:
WWARN

Responsibility for the Investigational product (IP) rests with the investigator/institution, and the PI/institution may need to receive IP for several sites at a central location before they are allocated to individual sites. This procedure therefore describes the process for central receipt (i.e. at first place of receipt) of IP for a clinical trial, including placing it in quarantine and adding it to a pharmacy inventory. This procedure may be supplemented with a trial-specific pharmacy manual or process document(s) and additional procedures relating to receipt at field trial sites.

Central receipt of investigational product

zip
13 April 2018
Central receipt of investigational product
2.0
zip
706.78 KB